Novo Nordisk A/S (NYSE:NVO) Trading Down 1.1% - Time to Sell?

Novo Nordisk A/S (NYSE:NVO - Get Free Report) shares traded down 1.1% during trading on Monday . The company traded as low as $77.82 and last traded at $77.94. 9,865,736 shares changed hands during mid-day trading, an increase of 3% from the average session volume of 9,598,048 shares. The stock had previously closed at $78.83.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Stock Performance

The stock has a fifty day simple moving average of $86.39 and a 200-day simple moving average of $108.48. The stock has a market cap of $376.02 billion, a P/E ratio of 25.47, a PEG ratio of 0.88 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is 21.88%.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of large investors have recently added to or reduced their stakes in NVO. Rosenberg Matthew Hamilton grew its holdings in shares of Novo Nordisk A/S by 2.5% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company's stock valued at $454,000 after acquiring an additional 94 shares in the last quarter. Spinnaker Trust grew its holdings in shares of Novo Nordisk A/S by 1.1% in the 3rd quarter. Spinnaker Trust now owns 9,615 shares of the company's stock valued at $1,145,000 after acquiring an additional 100 shares in the last quarter. Marco Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 1.5% in the 3rd quarter. Marco Investment Management LLC now owns 6,702 shares of the company's stock valued at $798,000 after acquiring an additional 100 shares in the last quarter. Carr Financial Group Corp grew its holdings in shares of Novo Nordisk A/S by 5.1% in the 3rd quarter. Carr Financial Group Corp now owns 2,100 shares of the company's stock valued at $250,000 after acquiring an additional 101 shares in the last quarter. Finally, Menard Financial Group LLC grew its holdings in shares of Novo Nordisk A/S by 0.8% in the 3rd quarter. Menard Financial Group LLC now owns 12,283 shares of the company's stock valued at $1,463,000 after acquiring an additional 102 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.